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ABSTRACT
The prognosis of patients with advanced hepatocellular carcinoma (HCC) is very 
poor. The AKT pathway is activated in almost half of HCC cases and in addition, long 
term exposure to conventional drug treatment of HCC, sorafenib, often results in over-
activation of AKT, leading to HCC resistance. Therefore, it is important to assess the 
safety and the efficacy of selective allosteric AKT inhibitor ARQ 092 (Miransertib) in 
combination with sorafenib.
Here, we demonstrated in vitro that the combination of ARQ 092 with sorafenib 
synergistically suppressed proliferation, promoted apoptosis, and reduced migration. 
To test the effect of the combination in vivo, rats with diethylnitrosamine-induced 
cirrhosis and fully developed HCC were randomized and treated with vehicle, sorafenib, 
ARQ 092 or the combination of ARQ 092 with sorafenib; (n=7/group) for 6 weeks. 
Tumor progression, size of tumors and the mean tumor number were significantly 
reduced by the combination treatment compared to the control or single treatments. 
This effect was associated with a significant increase in apoptotic response and 
reduction in proliferation and angiogenesis. Sirius red staining showed a decrease 
in liver fibrosis. Moreover, treatments improved immune response in blood and in 
tumor microenvironment.
Thus, the combination of ARQ 092 with sorafenib potentiates inhibition of tumor 
progression and gives the possibility of therapeutic improvement for patients with 
advanced HCC.
INTRODUCTION
Liver cancer (mainly hepatocellular carcinoma 
(HCC)) is reported to be the fifth most common cancer 
with second highest mortality among all cancers in adult 
men [1]. Viral hepatitis, chronic alcohol consumption 
and non-alcoholic steatohepatitis are the major causes of 
chronic liver inflammation which finally leads to HCC 
development. HCC that is diagnosed at an advanced 
stage has a very poor prognosis, and sorafenib is the 
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only approved drug available. The multikinase inhibitor 
sorafenib, originally developed as a Raf kinase inhibitor, 
targets the MAPK/ERK pathway but also the vascular 
endothelial growth factor receptors (VEGF-R) and 
the platelet-derived growth factor receptor (PDGF-R). 
Even though sorafenib is the first drug that significantly 
increases clinical outcome of advanced HCC, its efficacy 
is modest with a median overall survival of 10.7 months 
versus 7.9 months with placebo in the pivotal phase III 
trial [2]. Moreover, long-term exposure to sorafenib often 
results in reduced sensitivity of the tumor cells, leading to 
acquired resistance. Therefore, new therapeutic treatments 
of HCC with better efficacy are urgently needed.
Growing evidence indicates that the 
phosphatidylinositol-3 kinase (PI3K)/AKT/mTOR-
pathway is activated in approximately 50% of patients 
with cirrhosis and HCC [3, 4]. Moreover, sorafenib has 
been demonstrated to activate the AKT pathway in HCC 
cells [5] and this overactivation is considered to be one of 
the mechanisms of resistance to sorafenib treatment [6].
The serine/threonine kinase AKT, also known as 
protein kinase B or PKB, has become a major focus of 
attention mainly because of its critical role in regulating 
diverse cellular functions including metabolism, growth, 
proliferation, survival, transcription and protein synthesis. 
Activated AKT is known to inhibit apoptosis through its 
ability to phosphorylate several targets, including BAD, 
FoxO transcription factors, Raf-1 and caspase-9, that are 
critical for cell survival [7]. Therefore, the combination 
of sorafenib with an AKT-inhibitor could represent a new 
therapeutic strategy which could improve anti-tumor 
efficacy and overcome sorafenib resistance in HCC.
Recently, the combination strategy of sorafenib with 
mTOR inhibitors in HCC has been shown to be toxic and 
ineffective. Specifically, mTOR1 inhibitor everolimus 
in combination with sorafenib failed to show significant 
survival benefits compared to sorafenib alone [8]. 
Moreover, the same drug failed to demonstrate survival 
benefit in second line after failure of sorafenib, compared 
to placebo in a randomized phase 3 trial without patient’s 
selection [9]. It is necessary to emphasize that everolimus, 
similarly as other mTOR inhibitors, affects the mTORC1 
protein complex, and not the mTORC2. This leads to 
increased AKT phosphorylation via inhibition on the 
mTORC1 negative feedback loop, while maintaining the 
mTORC2 positive feedback to AKT [10].
In contrast with mTOR inhibitors, direct inhibition 
of AKT seems to be an effective and nontoxic strategy. 
In recent work, we have demonstrated anti-tumor efficacy 
of ARQ 092, a highly selective allosteric inhibitor 
[11] that suppresses pan-AKT activity by blocking its 
phosphorylation and by preventing the inactive form from 
localizing into plasma membrane which together leads to 
strong and specific downregulation of downstream targets 
of AKT. Such high specificity was missing in catalytic 
AKT inhibitors that have been previously developed 
[12]. In addition, it was recently demonstrated that AKT 
inhibitors may reverse the acquired resistance to sorafenib 
in vitro [13]. However, to our knowledge the effect of the 
combination therapy of sorafenib + highly specific AKT 
inhibitor was never tested on HCC in vivo.
Therefore, in this study we combined ARQ 092 with 
sorafenib to investigate whether this therapeutic strategy 
could provide an improvement in treatment of advanced 
HCC, without increased toxicity.
In order to identify specific adverse events that could 
be related to the background of cirrhosis, newly developed 
therapeutic strategies should be pre-clinically tested in a 
relevant animal model of HCC developed on a cirrhotic 
liver. One of the well-established models that at present 
best reproduces human cirrhosis is diethylnitrosamine 
(DEN)-injured rats [14]. Therefore, we used the DEN-
induced cirrhotic rat model with HCC to test safety and 
anti-tumor efficacy of the combination of sorafenib with 
AKT-inhibitor ARQ 092 (Supplementary Figure 1).
RESULTS
Combination of sorafenib and ARQ 092 
suppresses cell proliferation, promotes cell 
apoptosis, and reduces migration
We previously determined the half maximal 
inhibitory concentration (IC50) of single treatment on each 
cell lines ([11], Supplementary Table 1). To determine 
the effect of the combination treatment on cell growth, 
we used a mixture of IC50 of single treatments (i.e. 
IC50
Sorafenib+IC50
ARQ 092). MTT assays showed a drastic 
decrease in proliferation rate for Hep3B (Figure 1A), 
HepG2, Huh-7 and PLC/PRF cell-lines (Supplementary 
Figure 2A). The calculated combination index (CI) 
values (for details see supporting information), 
revealed strong synergistic effect of the combination 
treatment of sorafenib and ARQ 092 on cell growth as 
summarised in the Supplementary Table 2. Combination 
IC50/200 (IC50
Sorafenib+IC50
ARQ 092/200) and Combination 
IC50/10 (IC50
Sorafenib+IC50
ARQ 092/10) were used for further 
experiments.
We observed a significant decrease in cell-viability 
in the combination and single treated groups in all tested 
cell lines in comparison to the control (p<0.0001), (Figure 
1B and Supplementary Figure 3). Combination IC50/10 
significantly increased early apoptotic cells in Hep3B 
compared to sorafenib IC50 (p=0.003) or ARQ 092 IC50 
(p=0.023), (Figure 1B).
A wound-healing assay revealed that after 24h, 
the combination IC50/10 reduced migration of Hep3B 
significantly more than the sorafenib IC50 (Figure 1C, 
Supplementary Figure 4B). Moreover, in other cell lines, 
the migration of cells was decreased significantly in the 
combination IC50/10 treatment compared to both of the 
IC50 single treatments (Supplementary Figure 4A, 4B). 
Oncotarget11147www.impactjournals.com/oncotarget
Figure 1: Effect of Combination treatment on Hep3B cell viability, apoptosis and cell migration. (A) MTT assay on Hep3B 
cell line after 48h of treatments showing significant decrease in cell viability with increasing concentrations of combination treatment of 
ARQ 092 and sorafenib (constant ratio IC50: IC50). Combination index (CI = 0.053) at effective dose 50 (ED50) revealed strong synergy. 
(B) Additive effects of combination treatment of ARQ 092 and sorafenib on apoptosis in Hep3B after 48h of exposure. P values in graph 
represent ANOVA comparison of ARQ 092 IC50, sorafenib IC50 and Combination IC50/10. P value of ANOVA test of all groups is indicated 
in the corner of the graph (p <0.0001). (C) The quantification of migration (decrease of width of the wound after 24h) in Hep3B. Additive 
effects of combination treatment of ARQ 092 and sorafenib. P values in graph represent ANOVA comparison of ARQ 092 IC50, sorafenib 
IC50 and Combination I IC50/10. P value of ANOVA test of all groups is indicated in the corner of the graph (p =0.0001). Control was set as 
100%, values are means ± SE from three independent experiments performed in triplicates (A) and in duplicates (B, C).
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Similar results were obtained when cell velocity was 
assessed by cell tracking with time-lapse microscopy 
showing that wound-healing slow was related to cell 
migration inhibition and not decrease of cell proliferation 
(Supplementary Figure 4C).
All together, these results demonstrate that the 
combination of sorafenib and ARQ 092 synergistically 
suppresses cell proliferation, promotes cell apoptosis, 
and in an additive manner reduces migration in all tested 
human cell-lines.
Combination treatment in DEN-induced 
cirrhotic rat with HCC
To characterise the safety in a cirrhotic model and 
the anti-tumor efficacy of the combination of sorafenib 
and ARQ 092 in HCC, DEN-induced cirrhotic rats with 
HCC were treated during six weeks by sorafenib, ARQ 
092, the combination of both drugs or the untreated 
control group, as specified in Supplementary Figure 1. 
In a previous study, the treatment schedule of ARQ 092 
was 7 days on and 7 days off [11] but in this study, the 
schedule was changed to 5 days on and 9 days off in the 
ARQ 092 single treatment group and in the combination 
group to prevent possible side effects when combining 
with sorafenib treatment.
Safety data are summurized in Table 1. No 
significant differences in body weight were observed 
at the end of the treatment. The weight of the liver was 
lower in the ARQ 092 group compared to the control 
group, and in the combination group compared to the 
control and sorafenib group. Assessment of triglycerides 
in liver did not show any difference between groups 
(p=0.9743). Blood sample analysis revealed that none 
of treatments affect glucose, cholesterol or triglyceride 
blood concentrations. Similarly, kidney functions were 
not affected by treatments as plasmatic creatinine levels 
did not differ between groups. There was no statistical 
difference in transaminases, alkaline phosphatase (ALP) 
and prothrombin time among all groups. However, serum 
levels of AFP were significantly decreased by ARQ 092 
and the combination treatment compared to the control 
group. We observed a significant decrease in total 
bilirubin and an increase in albumin level in ARQ 092 
group compared to the control, and a decrease in GGT 
level in the combination group compared to the control. 
Table 1: Clinical and biological analyses
Control 
(n=7)
Sorafenib 
(n=7)
ARQ 092 
(n=7)
Combination 
(n=7)
ANOVA 
p-values
Body Weight (g) 290±7.4 291±2.0 270±6.0 274±5.6 ns
Liver Weight (g) 14.8±1.3 13.4±0.7 11.0±0.5* 10.9±0.5**,# 0.0026
TG (g/L) 28.9±4.4 30.5±3.4 29.1±3.0 30.1±2.1 ns
Blood Albumin (g/dL) 3.69±0.03 3.71±0.01 4.07±0.11*,## 3.76±0.05 0.0046
AFP (ng/mL) 0.82±0.17 0.44±0.12 0.33±0.09* 0.27±0.04* 0.0151
AST (U/L) 101.3±3.3 95.2±3.9 92.3±3.6 91.1±2.5 ns
ALT (U/L) 73.1±5.2 73.0±3.9 67.6±6.3 68.4±2.2 ns
ALP (U/L) 224±7.1 219±7.7 255±24.8 264±14.2 ns
GGT (U/L) 21.5±3.8 15.9±2.8 13.3±1.9 7.4±1.4** 0.0073
PT (s) 16.3±0.4 18.7±1.8 16.7±0.2 16.5±0.4 ns
Total Bilirubin (mg/dL) 0.21±0.01 0.18±0.01 0.16±0.01* 0.17±0.01 0.0211
Creatinine (mg/dL) 0.35±0.03 0.36±0.02 0.38±0.02 0.36±0.02 ns
GLU (mg/dL) 128±3.4 142±4.3 153±4.7 142±4.8 ns
Cholesterol (mg/dL) 86.6±6.5 84.9±4.0 102±7.3 88.7±5.1 ns
TG (g/L) 62.2±11.5 75.1±11.2 60.2±7.7 67.7±10.1 ns
Abbreviations: AFP, alphafetoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline 
phosphatase; GGT, Gamma-glutamyl transpeptidase; PT, Prothrombin time. Values are means ± SE. Significant difference 
compared to control; *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001. Significant difference between ARQ 092 and 
Sorafenib; ##: p<0.01.
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No difference was observed between the sorafenib and 
control groups.
Thus, our results showed that ARQ 092 and the 
combination treatment improve liver function but do not 
interfere with lipid or glucose metabolism (two major side 
effects of mTOR inhibitors).
The effect of ARQ 092, sorafenib and the 
combination of both agents on tumor progression was 
assessed by a liver MRI scan, Figure 2A. As illustrated in 
Figure 2B, tumor progression was significantly reduced 
by sorafenib (by 33.0±10.3%; p=0.005) and ARQ 092 
(by 33.8±10.6%; p=0.005) compared to the control. The 
greatest decrease in tumor progression rate was observed 
in the combination group when compared with the control 
(66.6±10.6%; p<0.0001), indicating an additive effect of 
sorafenib and ARQ 092 on the control of tumor progression. 
Similarly, the combination treatment significantly reduced 
tumor progression compared to sorafenib (50.1±13.3%; 
p=0.006) and ARQ 092 (49.6±14.1%; p=0.010).
MRI analyses were further confirmed by 
macroscopic examination of the liver (Figure 2C), 
which revealed significantly smaller mean tumor size in 
the sorafenib (6.3 ± 0.8 mm), ARQ 092 (6.2 ± 0.8 mm) 
and combination group (3.0 ± 1.1 mm) compared to the 
control rats (9.9 ± 1.1 mm) with statistical significance 
p=0.0092, p=0.0101 and p<0.0001, respectively. Mean 
tumor size in the combination group was significantly 
reduced compared to single agents, sorafenib (p=0.0187) 
or ARQ 092 (p=0.0308), confirming that the combination 
treatment is superior to the single agents.
The macroscopic counting of tumors revealed a 
significantly lower number in rats treated by ARQ 092 and 
the combination group compared to the control and sorafenib 
groups. In fact, while the mean number of tumors on the 
liver surface of the control rats was 109.5±14.5, significant 
reduction was observed in the ARQ 092 treated rats 
(31.5±14.8; p<0.0001) and in the combination (21.21±14.5; 
p<0.0001). Similarly, the ARQ 092 and combination groups 
displayed a significantly lower number of tumors compared 
to tumor numbers (69.21±11.5) in the sorafenib-treated 
animals (p=0.0188 and p=0.0016 respectively), Figure 2C. 
Accordingly, the frequency of Ki67-positive nuclei was 
significantly reduced in ARQ 092 (p=0.0421) and in the 
combination group (p=0.0206) compared to the control 
group. The combination treatment also significantly reduced 
the Ki67 proliferation marker compared to sorafenib group 
(p=0.0487), Figure 2D. TUNEL immunostaining showed 
that only the combination group significantly induced 
apoptosis (p=0.0272), Figure 2E. The sorafenib treatment 
showed no statistical significance for Ki67 (89.8 ± 12.1 % 
of control, p=0.9563) or TUNEL (124.9 ± 9.6 % of control, 
p=0.4566), Figure 2D and 2E.
Real time qPCR analyses of alpha fetoprotein (AFP), 
HCC tumor marker, showed a reduced expression in all 
treated groups compared to the control (Figure 2F), with a 
much stronger effect in the combination group (p=0.0138).
Overall, we observed an additive effect of the 
combination of sorafenib and ARQ 092 on tumor 
progression and tumor size. Moreover, the combination 
significantly reduced tumor proliferation in DEN-induced 
HCC rat model, and was clearly more effective than 
sorafenib and/or ARQ 092 monotherapies.
Effect of combination treatment on tumor 
vascularization and liver fibrosis
Anti-angiogenic effect of treatment was determined 
by immunostaining of liver tissue, using a rat-specific 
anti-CD34 antibody. Major structural abnormalities of the 
vasculature were observed in control livers, and tissues 
from all treated groups demonstrated normalization of 
vasculature, Figure 3A. Similarly, the quantification of 
vascular density revealed that both sorafenib and ARQ 
092 significantly decreased angiogenesis, but to smaller 
extent than the combination treatment. In fact, sorafenib 
decreased vascular density by 30% (p=0.0012), ARQ 
092 by 58% (p<0.0001) and the combination by 75% 
(p<0.0001) compared to non-treated rats (Figure 3B). 
The gene expression of hypoxia-inducible factor (HIF-
1), considered a marker of tumor hypoxia, tended to be 
decreased by all treatments but only the combination 
treatment significantly reduced HIF-1 expression in tumor 
tissue compared to the control (p=0.0194), Figure 3C.
Liver fibrosis was analyzed by Sirius red staining. 
As shown in Figure 3D and 3E, fibrotic tissues were 
significantly reduced in the ARQ 092 and combination 
groups compared to the control and sorafenib groups.
Improvement of liver fibrosis by ARQ 092 and the 
combination treatment was confirmed by qPCR analysis 
of non-tumoral tissue (Figure 3F). The expression of 
markers of liver fibrosis (alpha smooth muscle actin 
(α-SMA), collagen 1 and transforming growth factor β1 
(TGFβ 1)) was significantly downregulated in non-tumor 
liver samples in ARQ 092 and the combination groups 
compared to the control group. Accordingly, the tissue 
inhibitor of metalloproteinases-1 (TIMP-1) was decreased 
by all treatments compared to the control whereas matrix 
metalloproteinases MMP2 and MMP9 were significantly 
upregulated in the combination group compared to the 
control and sorafenib groups. This effect on the matrix 
pathway was specific for non-tumor tissue. Thus, ARQ 
092 and the combination treatment significantly decreased 
hepatic collagen deposition and improved liver fibrosis in 
DEN-induced cirrhotic rats, while sorafenib only had a 
mild effect.
Effect of combination treatment on AKT and 
ERK pathway
Western blot analyses showed that ARQ 092 and the 
combination of ARQ 092 with sorafenib treatment blocked 
phosphorylation of AKT(Ser473) in all human HCC cell 
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Figure 2: Anti-tumor effect of combination treatment. (A) Representative pictures of abdominal MRI 1, 2 and 3 scan of non-
treated rat and rat treated by combination treatment. (B) Tumor progression assessment by comparison of tumor size on MRI 1, 2 and 3 in 
Control, sorafenib, ARQ 092 and Combination group. (C) Macroscopic examination of livers with assessment of tumor size (middle panel) 
and tumor number at the surface of livers (right panel). (D) Representative images of nuclear Ki67 staining (arrow), 20x magnification with 
quantification of Ki67 staining per high power field (HPF). (E) Representative images of apoptosis induction (right panel) determined by 
TUNEL immunostaining (arrow), 20x magnification with quantification of apoptotic cells per HPF. (F) qPCR analysis of alpha fetoprotein 
(AFP) gene expression in tumor liver samples. The scale of the Y axes are Log 10, control was set as 1, values are means ± SE, n=7/group. 
Comparison of means was done by ANOVA test with Tukey correction.
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lines at both IC20 and IC50 concentrations (Supplementary 
Figure 5).
In the in vivo model, ARQ 092 and the combination 
treatment strongly inhibited phosphorylation of AKT(Ser473) 
in both tumor and non-tumor liver tissues (Figure 4A and 
4B). qPCR analyses demonstrated a significant decrease 
in AKT gene expression in tumor tissue of the ARQ 092 
and combination treated groups compared to the control 
group. This effect was expected as ARQ 092 inhibitor 
blocks AKT phosphorylation and prevents the inactive 
form from localizing into plasma membrane, protein levels 
of AKT are stable but AKT gene expression is decreased. 
Moreover, ARQ 092 and the combination treatment 
strongly downregulated the AKT-pathway downstream 
effector mTORC1 specifically in tumoral tissue while 
there is no significant difference in non-tumoral tissue. 
Ribosomal protein S6 kinase beta-1 (S6K1), another 
downstream effector of AKT and mTORC1, was 
significantly decreased by ARQ 092 and the combination 
in both tumoral and non-tumoral liver tissue.
Next, we studied whether sorafenib still inhibits 
the MAPK/ERK pathway or whether cells are already 
resistant to sorafenib. There was no difference in pERK/
ERK ratio among all groups (Figure 4A and 4B) and 
MAPK1 mRNA levels were not altered among all groups 
(Figure 4C).
Effect of treatment on immune system and 
tumor microenvironment
To characterize the effect of treatment on the 
immune system, whole fresh blood was analyzed by flow 
cytometry. Immune cells were identified based on CD45 
expression and different populations of lymphocytes were 
then identified accordingly to their respective rat-specific 
markers: NK (CD161high+CD3-), NKT (CD161low+CD3+) 
and T (CD161-CD3+), Figure 5A. No difference in 
frequency of circulating NK or NKT cells was observed 
between groups (Supplementary Table 3). Interestingly, the 
frequency of T-cells in population of CD45+ was increased 
Figure 3: Effect of Combination treatment on tumor vascularization and liver fibrosis. (A) Representative pictures of CD34 
immunofluorescence staining of liver tissue. (B) Quantification of CD34 staining, control was set as 100, values are means ± SE. (C) qPCR 
analysis of Hypoxia-inducible factor (HIF)-1 gene expression in tumoral and non-tumoral liver samples. Control was set as 1. Values are 
means ± SE. N=7/group. Comparison of means was done by ANOVA test with Tukey correction. (D) Representative histological images of 
livers stained with Sirius red. (E) Quantification of Sirius red staining area per total area; control was set as 100 %. (F) qPCR analysis of 
alpha smooth muscle actin (α-SMA), Collagen (COL)1, TIMP Metallopeptidase Inhibitor 1 (TIMP1), Matrix metalloproteinase-2 (MMP2), 
Matrix metalloproteinase-9 (MMP9) and transforming growth factor (TGF)β gene expression in non-tumoral liver tissue. The scale of the 
Y axes are Log 10, control was set as 1. Values are means ± SE. N=7/group. Comparison of means was done by ANOVA test with Tukey 
correction.
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Figure 4: Effect of Combination treatment on AKT and ERK pathways. Western blot analysis of pAKT/AKT and pERK/ERK 
in (A) tumoral and (B) non-tumoral liver tissue. pAKT and pERK were stained first and after development, the membranes were stripped 
followed by staining of AKT and ERK. (C) qPCR analysis of the expression of AKT, MAPK, mTOR, S6K1 in tumoral (upper panel) 
and non-tumoral (lower panel) liver tissue. The scale of the Y axes are Log 10, control was set as 1, values are means ± SE. N=7/group. 
Comparison of means was done by ANOVA test with Tukey correction.
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Figure 5: Effect of combination treatment on immune system and tumor microenvironment. (A) Gating flow cytometry 
strategy to investigate immune cells. Lymphocytes were first identified according their FSC and SSC parameters and further gated based 
on their CD45+ expression. Among the CD45+ population, NK (CD161high+CD3-), NKT (CD161low+CD3+) and T (CD161-CD3+) cells were 
selected. (B) Granulocytes to lymphocytes ratio. Values are means ± SE. N=7/group. Comparison of means was done by ANOVA test 
with Tukey correction. (C) Representative histological images of livers stained with myeloperoxidase and the quantification of positive 
cells (neutrophils) per high power field (HPF). (D) Representative histological images of livers stained with CD68 and the quantification 
of positive cells (macrophages) per HPF. (E) Expression of CD47 in tumor liver tissue and quantification of mean fluorescence intensity 
(MFI) of CD47, sorafenib (grey line), ARQ 092 (purple line). Values are means ± SE. N=7/group. Comparison of means was done by 
ANOVA test with Tukey correction.
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by ARQ 092 and the combination treatment compared to 
control and sorafenib. This effect was accompanied by a 
strong reduction in the number of circulating granulocytes 
(Supplementary Table 3), which together led to significant 
reduction of Granulocyte/T cell ratio, Figure 5B.
In liver tissue, flow cytometry analyses showed 
no differences in the population of T-cells, NK cells or 
NKT cells between experimental groups. Similarly, 
by immunohistochemistry, we observed no significant 
differences between groups in the frequency of intrahepatic 
CD3- and CD8-positive cells (data not shown).
In accordance with the decrease in granulocytes 
frequency in blood, we observed a significant decrease 
in accumulated neutrophils in the liver tissue of all 
treated groups compared to control, as determined by 
myeloperoxidase staining, Figure 5C. Another population 
of immune cells, which was significantly reduced in the 
tumor microenvironment of the treated animals compared 
to control, were macrophages. We observed significant 
reduction of CD68+ cells in rats treated by the combination 
treatment compared to control group, Figure 5D.
Tumor-initiating cells are characterized by high 
expression of CD47 [15]. Moreover, over-expression 
of CD47 is involved in sorafenib resistance [16]. Flow 
cytometry analyses revealed that highly expressing CD47 
population in liver tissue was decreased by all treatments, 
with a significant effect in the combination group (Figure 
5E).
All together, our data demonstrated that the 
combination treatment improves anti-tumor immune 
balance in the tumor itself and in blood, potentially 
explaining in part the anti-tumor effect of this combination. 
Moreover, the combination treatment significantly 
decreased a population of tumor-initiating cells.
DISCUSSION
The heterogeneity of HCC is both genetic [17] and 
phenotypical/morphological [18], with the hallmarks 
of cancer exhibited in a complex manner such as 
localizations and times. This complex and multivariate 
tumor network that constantly responds to and influences 
liver environment is the main reason of the limited success 
of different targeted monotherapies tested in HCC [19]. 
Thus, combining multiple anti-cancer drugs seems to be 
a rational approach in the prevention of tumor resistance. 
Nonetheless, as this strategy usually induces a huge 
increase of toxicity, there is an urgent need to find well-
tolerated and effective combinations of targeted therapy to 
treat HCC patients.
HCC is a hypervascularized tumor with an 
anarchic neoangiogenesis and is usually surrounded 
by a cirrhotic liver. These characteristics obviously 
influence drug metabolism, by making systemic drug 
delivery less effective and by leading to severe adverse 
events. Therefore, before testing the safety and efficacy 
of multitarget therapies in clinical trials, pre-clinical 
studies are essential and the most optimal animal model 
need to be chosen. Thus, to test the combination of 
sorafenib and the AKT inhibitor ARQ 092, we used a 
cirrhotic rat model with HCC that closely reproduce 
human HCC physiopathology. We observed that the 
combination of ARQ 092 with sorafenib additively 
reduced tumor progression and tumor size with a 
significant higher efficacy than sorafenib and ARQ 092 
monotherapies. The anti-tumor effect was associated 
with a significant reduction of tumor cell proliferation 
and an increased apoptosis in vivo. Treatment of ARQ 
092 showed marked reduction of tumor number similar 
to the combination treatment, whereas sorafenib only had 
a modest effect on tumor initiation. Similarly, the cell 
proliferation, determined by Ki67 staining, was strongly 
reduced exclusively by ARQ 092, suggesting that AKT 
inhibition may even block tumor initiation. To confirm 
this hypothesis in our animal model, further experiments 
with an earlier introduction of ARQ 092 (during the DEN-
induction phase) are needed.
Sorafenib-ARQ 092 combination therapy was 
very successful not only in targeting the tumor, but 
also in amelioration of liver microenvironment. This 
is particularly important, because after HCC initiation, 
the tumor progression is finely regulated by tumor 
microenvironment which even later influences the 
tumor response to therapies. For instance, increased and 
irregular vasculature will allow small HCC lesions to 
progress and metastasize, which is a typical situation in 
the fibrotic liver characterised by constantly increased 
formation of blood vessels [20]. The mechanism of 
beneficial action of sorafenib on liver vascularisation 
was described previously [21]. Here, we showed that 
the combination of ARQ 092 and sorafenib improved 
the vascularization of liver tissue in an additive manner 
and additionally decreases expression of HIF-1 in tumor 
tissue. Similarly, the anti-fibrotic effect of sorafenib was 
clearly demonstrated by numerous experimental studies 
(reviewed in [22]). In our study, the anti-fibrotic effect 
of sorafenib was relatively modest. On the contrary, the 
sorafenib-ARQ 092 combination greatly shifted matrix 
regulatory pathway, leading to fibrosis resolution with 
a strong decrease of collagen accumulation. Another 
essential determinant of HCC progression and survival is 
cancer-associated inflammation, with TGFβ orchestrating 
a favorable microenvironment for tumor cell growth. Here 
we showed that expression of TGFβ in non-tumor tissue 
was downregulated in an additive way by sorafenib-ARQ 
092 combination.
Recently, a meta-analysis showed that a high 
neutrophil-to-lymphocyte ratio indicates a poor prognosis 
in patients with HCC, representing a shift towards 
an increased pro-tumor inflammation and decreased 
anti-tumor immune functions [23, 24]. In our model, 
all treatments significantly decreased granulocyte-to-
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lymphocyte ratio compared to the control. The strong 
reduction of circulating neutrophils in rats treated by 
ARQ 092 monotherapy should to be taken into account. 
In fact, ARQ 092 was recently used to block neutrophils 
and decrease inflammation in sickle cell disease [25]. 
However, because neutrophils are the first responders to 
sites of acute injury and infection, the effect of ARQ 092 
on circulating neutrophils needs to be mentioned.
The frequency of liver infiltrating neutrophils was 
similarly reduced by all treatments, while accumulation of 
macrophages was additively decreased by the sorafenib-
ARQ 092 combination. This is particularly important as 
there is growing evidence of the key-role of neutrophils 
and macrophages in liver fibrosis and HCC progression 
[26–28]. On the other hand, we did not find significant 
changes in intrahepatic T-cells. However, we may not 
be able to study particular T-cell subpopulations due to 
specificity of antibodies against rat.
Despite difficulties induced by the presence of a 
cirrhosis in our DEN-rat model of HCC, the sorafenib-
ARQ 092 combination showed enhanced efficacy with 
a good safety profile. The dose strategy 5 days on - 9 
days off for ARQ 092 was based on a toxicity study 
(unpublished data) with very good tolerance. Similarly, to 
decrease sorafenib toxicity, the concentration of 10 mg/kg 
was used. In fact, our pilot experiments showed that in 
cirrhotic rats treated with sorafenib, a dose of 20 mg/kg 
causes severe adverse events including an important 
weight loss, demonstrating the complexity of HCC 
treatment and the importance of using an appropriate 
animal model to test HCC treatment efficacy and safety.
We identified a novel treatment choice for 
advanced HCC with cirrhotic background. The resutls 
from in vitro and in vivo studies clearly illustrated the 
significance of targeting AKT pathways that potentiates 
sorafenib treatment of HCC. The safety and efficacy of 
this combination strategy provides the possibility of 
improvement of therapeutic outcomes for advanced HCC 
patients.
MATERIALS AND METHODS
Cell lines and in vitro studies
In this study, we used three different human HCC 
cell lines (Hep3B, HuH7, and PLC/PRF/5) and one 
hepatoblastoma cell line (HepG2). While Hep3B is p53-
depleted, HuH-7 and PLC/PRF/5 present p53 mutations 
and HepG2 is a wild-type p53-expressing cell line. No 
mutations in AKT were detected in mentioned cell lines 
(COSMIC database). Expression of p-AKT was reported 
to be normal in Hep3B and low in HepG2, HuH-7 and 
PLC/PRF/5 cell lines [4]. Culture conditions are described 
in supporting information.
A cell viability assay was performed by MTT 
(3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide), apoptosis was assessed by flow cytometry 
analysis and cell migration was studied using a wound 
healing assay and by cell tracking with time-lapse 
microscopy as described in supporting information.
Preparation of treatments
Preparation of ARQ 092 (ArQule Inc, USA), 
sorafenib (in vitro study: Bay 43-9006, Sigma-Aldrich, 
Germany; in vivo study: Nexavar®, Bayer HealthCare, 
Germany) and the combination treatment for in vitro and 
in vivo experiments is described in detail in the supporting 
information.
Rat model and groups of treatment
Twenty-eight 6-week-old Fischer 344 male rats 
(Charles River Laboratories, France) were housed in 
the animal facility of Plateforme de Haute Technologie 
Animale (Jean Roget, University of Grenoble-Alpes, 
France). Rats were treated weekly with intra-peritoneal 
injections of 50 mg/kg of diethylnitrosamine (DEN) 
(Sigma-Aldrich, Germany), diluted in olive oil in order 
to obtain a fully developed HCC on a cirrhotic liver 
after 14 weeks [14]. Rats were randomized in 4 different 
groups (n=7/group) and treated during six weeks by i) 
sorafenib, ii) ARQ 092, iii) combination of ARQ 092 and 
sorafenib or iv) rested untreated (control), as specified in 
Supplementary Figure 1. ARQ 092 alone, sorafenib alone 
and combination (Sorafenib plus ARQ 092) treatments 
were dispensed by oral gavage for a period of six weeks. 
ARQ 092 treatment was administered 5 days on 9 days 
off, at the dose of 15 mg/kg/day for single treatment group 
same as for combination group, as recommended by the 
ArQule Inc. Sorafenib was administered continuously 
at the dose of 10 mg/kg/day for single treatment group 
as well as for the combination group. We used 10 
mg/kg/day because igher concentrations of sorafenib 
were demonstrated to be toxic for cirrhotic rats ([11], pilot 
experiments and personal communication with Bayer AG).
Nutritional state was monitored by daily weighing 
of rats and protein-rich nutrition was added to the standard 
food in every cage where a loss of weight was observed. 
Food was withheld for 3-4 hours before animals were 
sacrificed.
All animals received humane care in accordance 
with Guidelines on the Humane Treatment of Laboratory 
Animals, and experiments were approved by the animal 
Ethic Committee: GIN Ethics Committee n°004.
MRI studies
The imaging study was conducted on a 4.7 Tesla MR 
Imaging system (BioSpec 47/40 USR, Bruker Corporation, 
Germany). As illustrated in Supplementary Figure 1, all 
rats were subjected to 3 MRI scans: MRI1 was performed 
before randomization, MRI2 was performed after 3 weeks 
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of treatment and MRI3 after 6 weeks of treatment. The 
protocol for image acquisition and analysis is detailed 
in supporting information. MRI analysis was done by an 
investigator who was blinded of treatment allocation.
Histopathological, immunohistochemical and 
immunofluorescence analyses
After the third MRI scan, all rats were euthanized 
with vena cava blood sampling for haematologic and 
biochemical analyses. Each liver was weighed, the 
diameter of the five largest tumors was measured and 
the number of tumors larger than 1 mm on the surface 
of the liver was counted, all in a blinded manner. Tumor 
proliferation and apoptosis were studied by using anti-
Ki67 antibody and TUNEL marker. Tissue vascularization 
was determined by CD34 immunostaining. Histological 
analysis of fibrosis was performed by sirius red-staining of 
collagen. Analyses were performed in collaboration with 
experienced pathologist (CHU-Grenoble Département 
d’Anatomie et de Cytologie Pathologiques). Protocols are 
described in supporting information.
Serum and plasma were tested for liver and kidney 
safety markers (albumin, ALP, ALT, AST, prothrombin 
time, total bilirubin, cholesterol, GGT, glucose, creatinine, 
Table 1) by Charles River Clinical pathology Services 
using Olympus and Stago instruments. Liver triglycerides 
were measured as described previously [11].
Pathways analysis
Western blot analysis of pAKT(Ser473)/AKT and 
pERK/ERK, and real-time polymerase chain reaction 
(qPCR) analyses were performed on tumor and non-
tumor tissues. Protocols are described in the supporting 
information.
Flow cytometric analysis
Cells were recovered from liver tissue by 
mechanical disruption as described previously [29] and 
whole blood samples were used in case of blood analyses. 
Cells without any stimulation were immune-stained for 
flow cytometric analysis. The protocol is described in the 
supporting information.
Statistical analysis
All comparisons of means were calculated by using 
ANOVA tests with Tukey HSD correction for multiple 
means comparisons, and independent T-tests only when 
two means were compared. Data are presented as mean 
values ± standard error mean (SEM). Statistical analyses 
were performed using Prism 6 (GraphPad Software Inc., 
CA, USA).
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